A significant international study has identified a 14-protein blood signature that may predict lung cancer risk more than five years before diagnosis. Conducted by researchers from the Walter and Eliza Hall Institute of Medical Research in Australia, the study analyzed about 48,000 blood samples and found that this signature is linked to chronic inflammation rather than existing tumors. Early detection is crucial, as survival rates for lung cancer are heavily influenced by stage at diagnosis; early-stage lung cancer has a five-year survival rate of over 60%, compared to just 6% for advanced cases. The study suggests that this blood test could enhance screening programs, particularly for individuals who do not meet current criteria, such as former smokers. Additionally, it raises the possibility of prevention strategies through anti-inflammatory treatments for those identified as high-risk. However, researchers caution that the test is not yet ready for clinical application and requires further validation, including addressing false-positive rates and integration into existing screening protocols. If successful, this could transform lung cancer detection and prevention, especially in regions with limited access to advanced imaging.